Table 3.

Subgroup analysis of CD80, PD-L1, FOXP3, CD40 and CD14 mRNA expression in MBC patients

Effect	No.	CD80			PDL1			FOXP3			CD40			CD14
		Mean	SD	p value	Mean	SD	p value	Mean	SD	p value	Mean	SD	p value	Mean	SD	p value
Age
≤60	13	1.79	1.07		3.12	2.35		3.14	2.64		1.45	0.58		1.50	0.98
>60	17	2.09	1.00	0.44	2.10	0.84	0.11	2.79	1.50	0.66	1.40	0.57	0.81	1.82	0.85	0.36
Number of metastatic sites
1, 2	16	2.07	1.17		2.54	0.92		3.09	2.40		1.44	0.62		1.39	0.71
3, 4	14	1.83	0.86	0.53	2.54	2.36	0.99	2.77	1.61	0.67	1.40	0.52	0.84	2.01	1.00	0.06
Prior therapy for MBC
No prior therapy	5	2.44	1.26		2.91	1.32		2.20	1.52		1.76	0.61		1.64	1.04
Endocrine therapy	14	1.90	0.82	0.29	2.92	2.20	0.99	2.90	1.08	0.28	1.44	0.47	0.24	1.72	1.03	0.88
Cytotoxic chemotherapy	13	1.88	1.05	0.35	2.10	0.98	0.16	3.14	2.86	0.50	1.20	0.56	0.08	1.61	0.91	0.95
Anti-HER2 therapy	7	1.44	0.75	0.12	1.76	1.01	0.06	4.07	3.67	0.29	1.08	0.52	0.03	1.58	0.78	0.91